Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation

作     者：Almurtada Razok Fateen Ata Sara Mohamed Ibrahim Ahmed Dabia Hamad S H Al Mohanadi 

作者机构：Department of Internal MedicineHamad Medical CorporationDoha 3050Qatar Department of EndocrinologyHamad Medical CorporationDoha 3050Qatar 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2022年第13卷第3期

页      面：272-274页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Euglycemic diabetic ketoacidosis Sodium-glucose co-transporter 2 inhibitors Type 2 diabetes mellitus Empagliflozin 

摘      要：Euglycemic diabetic ketoacidosis(EDKA)is a well-known complication of sodium-glucose co-transporter 2 inhibitors,and many cases with variable onset following the initiation of these agents are reported before,with a median onset of approximately 2 *** letter discusses a 45-year-old lady who initially presented with ischemic stroke but developed EDKA 4 d after starting empagliflozin,a rare *** patient had severe metabolic acidosis that necessitated admission into the intensive care *** discontinuation of empagliflozin and DKA management resulted in clinical recovery.